Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-11-15
2005-11-15
Flood, Michele (Department: 1654)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S215000, C435S217000
Reexamination Certificate
active
06964764
ABSTRACT:
Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.
REFERENCES:
patent: 3136703 (1964-06-01), Singher
patent: 3434929 (1969-03-01), Buck et al.
patent: 3950513 (1976-04-01), Jensen
patent: 4082612 (1978-04-01), Robbins et al.
patent: 4115551 (1978-09-01), Lormeau et al.
patent: 4177262 (1979-12-01), Lormeau et al.
patent: 4259448 (1981-03-01), Nakamura et al.
patent: 4361652 (1982-11-01), Uemura et al.
patent: 4361653 (1982-11-01), Watanabe et al.
patent: 4442213 (1984-04-01), Heber et al.
patent: 4446316 (1984-05-01), Chazov et al.
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: 4663146 (1987-05-01), Morser et al.
patent: 4774087 (1988-09-01), Wu et al.
patent: 4908204 (1990-03-01), Robinson et al.
patent: 5024829 (1991-06-01), Berger et al.
patent: 5096637 (1992-03-01), DiLeo et al.
patent: 5165912 (1992-11-01), Selmer et al.
patent: 5237050 (1993-08-01), Boyle et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5290692 (1994-03-01), Suzuki et al.
patent: 5304383 (1994-04-01), Eibl et al.
patent: 5328996 (1994-07-01), Boyle
patent: 5371007 (1994-12-01), Linnau et al.
patent: 5407673 (1995-04-01), Reich et al.
patent: 5472692 (1995-12-01), Liu et al.
patent: 5728674 (1998-03-01), Sprecher et al.
patent: 5767269 (1998-06-01), Hirsh et al.
patent: 5776452 (1998-07-01), Eibl et al.
patent: 5879923 (1999-03-01), Yago et al.
patent: 6139819 (2000-10-01), Unger et al.
patent: 6207066 (2001-03-01), Trese et al.
patent: 1 167 823 (1997-12-01), None
patent: 0 399 321 (1990-11-01), None
patent: 904478 (1962-08-01), None
patent: 0207 8633 (1990-03-01), None
patent: 09 065895 (1997-03-01), None
patent: 103 682 (1991-12-01), None
patent: WO 87/06836 (1987-11-01), None
patent: WO 93/15189 (1993-08-01), None
patent: WO 95 04077 (1995-02-01), None
Robbins, KC et al., Journal of Biological Chemistry (1963), 238: 952-62. Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on Diethylaminoethyl-Sephadex.
Dupe, RJ et al., Thrombosis and Haemostasis (1981), 51(2): 248-253. Acyl-enzymes as thromblytic agents in dog models of venous thrombosis and pulmonary embolism.
Beathard, GA. Kidney International (1994), 45:1401-1406. Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts.
Abe, T. Proc. Intern. Cong. Hematol. (1962), 3: 1587-39. Fibirinolytic influence of monocarboxylic acids and some other substances.
Kline, D.L., “The Purification and Crystallization of Plasminogen(Profibrinolysin),”Journal of Biological Chemistry, 204: 949-955 (1953).
Supplementary Partial European Search Report (EP 00 99 1956, dated Dec. 17, 2004).
Jespersen, J., et al., “The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition,”Thromb. Res. 41(3):395-404 (1986).
Johnson, A.J., et al., “Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems, 1967-1968,”Thromb. Diath. Haemorrh., 21(2):259-72 (1969).
Kirkwood, T.B.L., et al., “A standard for human plasmin,”Thromb. Diath. Haemorrh., 34(1):20-30 (1975).
Kline, D.L. and J.B. Fishman, Preparation, Stabilization and Some Properties of Purified Human Plasmin,Thromb. Diath. Haemorrh., 11:75-84 (1964).
Ling, C.M., et al., “Mechanism of formation of bovine plasminogen activator from human plasmin,”J. Biol. Chem., 240(11):4213-8 (1965).
Nahum, L.H., et al., “Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis,”Conn. Med. 24:139-46 (1960).
Robbins. K.C., et al., “The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin,”J. Biol. Chem., 242(10):2333-42 (1967).
Sgouris, J,T, et al. “The preparation of human fibrinolysin (plasmin),”Vox Sang., 5:357-76 (1960).
Summaria, L., et al., “Recombinant human Lys-plasmin and the Lys-plasmin-streptokinase complex,”J. Biol. Chem., 254(14):6811-4 (1979).
Summaria, L., et al., “The specific mechanism of activation of human plasminogen to plasmin,”J. Biol. Chem., 242(19):4279-83 (1967).
Ueshima, S., et al., “Stabilization of plasmin by lysine derivatives,”Clin. Chim. Acta., 245(1):7-18 (1996).
Wohl, R.C., et al., “Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37°C,”J. Biol. Chem., 255(5):2005-13 (1980).
Wohl, R.C., et al., “Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various activated forms of human plasminogen,”J. Biol. Chem., 253(5):1402-7 (1978).
Binder, B.R., et al., “Purification and Characterization of Human Vascular Plasminogen Activator Derived from Blood Vessel Perfusates,”Journal of Biological Chemistry, 254(6): 1998-2003 (1979).
Castellino, F.J., et al., “Rabbit Plasminogen and Plasmin Isozymes,”Methods in Enzymology, 45: 273-286 (1976).
Robbins, K.C., et al., “Human Plasminogen and Plasmin,”Methods in Enzymology, 19: 184-199 (1970).
International Search Report (PCT/US03/34020, dated Jul. 27, 2004).
European Supplementary Partial Search Report (EP 00 97 8572, dated Jul. 16, 2004).
European Supplementary Partial Search Report (EP 00 99 1956, dated Jun. 1, 2004).
European Supplementary Partial Search Report (EP 00 99 0910, dated May 25, 2004).
Ambrus, C., et al., “Insolubilized Activators of the Fibrinolysin System,”J. Med. 3:270-281 (1972).
Ambrus, J.L., et al., “Clinical Pharmacology of various types of fibrinolytic enzyme preparations,”Am. J. Cardiol., 6:462-475 (1960).
Amris, C.J., et al., “Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer,”Danish Medical Bulletin, 11(5):141-145 (1964).
Amris, C.J., et al., “Turnover and Distribution of131I-Labelled Procine Plasmin in Man and Dog,”Danish Medical Bulletin, 11(5):146-152 (1964).
Anlyan, W., et al., “Experiences with Fibrinolysin in Peripheral Vascular Occlusive Disease,”Am. J. Cardiol., 6:507-512 (1960).
Barrett, A.J., et al., “The Electrophoretically ‘Slow’ and ‘Fast’ Forms of the α2-Macroglobulin Molecule,”Biochem. J., 181:401-418 (1979).
Boucek, R., et al., “Segmental Perfusion of the Coronary Arteries with Fibrinolysin in Man Following a Myocardial Infarction,”Am. J. Cardiol., 6:525-533 (1960).
Boyles, P.W., et al., “Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy,”Am. J. Cardiol., 6:439-446 (1960).
Castellino, F.J. and J.R. Powell, “Human Plasminogen,”Meth. Enzymology, 80:365-378 (1981).
Collen, D., et al., “Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration,”J. of Clin. Invest., 71(2):368-376 (1983).
Deutsch, D.G. and E.T. Mertz, “Plasminogen: purification from human plasma by affinity chromatography,”Science 170:1095-1096 (1970).
Freitag, H., et al., “Lys-plasminogen as an Adjunct
Jesmok Gary J.
Landskroner Kyle A.
Novokhatny Valery
Taylor Kathryn K.
Zimmerman Thomas P.
Flood Michele
Talecris Biotherapeutics, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Method of thrombolysis by local delivery of reversibly... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of thrombolysis by local delivery of reversibly..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of thrombolysis by local delivery of reversibly... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469866